肿瘤
腫瘤
종류
TUMOR
2010年
4期
338-342
,共5页
癌,非小细胞肺%厄罗替尼%治疗结果%药疹
癌,非小細胞肺%阨囉替尼%治療結果%藥疹
암,비소세포폐%액라체니%치료결과%약진
Carcinoma,non-small cell lung%Erlotinib%Treatment outcome%Drug eruptions
目的:评价厄罗替尼所致皮疹与临床疗效之间的关系,并探讨皮疹治疗的有效方法.方法:研究对象为2005年12月-2008年9月接受厄罗替尼治疗并发生皮疹的76例晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者,均经病理组织学或细胞学予以确诊.厄罗替尼治疗方案为150 mg/d,每日连续服药直至疾病进展或出现不可耐受的不良反应.记录皮疹严重度,按照美国国立癌症研究院通用毒性标准(National Cancer Institute-Common Toxicity Criteria, NCI-CTC)对皮疹严重度进行分级,并观察其治疗结局.结果: 76例患者发生皮疹的中位时间为8 d,其中1度皮疹27例(35.5%)、2度皮疹44例(57.9%)、3度皮疹5例(6.6%).1度和2～3度皮疹的疾病控制率分别为63.0%(部分缓解5例、稳定12例)和91.8%(部分缓解32例、稳定13例),差异有统计学意义(P＜0.05).1度皮疹和2～3度皮疹患者的中位疾病进展时间分别为5.1和9.7个月(P＜0.01).1度皮疹患者的中位生存期为10.0个月,2～3度皮疹患者的中位生存期为14.6个月(P＜0.01).有78.9%(60/76)的患者经治疗后皮疹得到缓解.结论:厄罗替尼所致皮疹是厄罗替尼临床获益的指标之一,且大多数患者可以耐受,给予恰当的治疗后可以获得缓解.
目的:評價阨囉替尼所緻皮疹與臨床療效之間的關繫,併探討皮疹治療的有效方法.方法:研究對象為2005年12月-2008年9月接受阨囉替尼治療併髮生皮疹的76例晚期非小細胞肺癌(non-small cell lung cancer, NSCLC)患者,均經病理組織學或細胞學予以確診.阨囉替尼治療方案為150 mg/d,每日連續服藥直至疾病進展或齣現不可耐受的不良反應.記錄皮疹嚴重度,按照美國國立癌癥研究院通用毒性標準(National Cancer Institute-Common Toxicity Criteria, NCI-CTC)對皮疹嚴重度進行分級,併觀察其治療結跼.結果: 76例患者髮生皮疹的中位時間為8 d,其中1度皮疹27例(35.5%)、2度皮疹44例(57.9%)、3度皮疹5例(6.6%).1度和2～3度皮疹的疾病控製率分彆為63.0%(部分緩解5例、穩定12例)和91.8%(部分緩解32例、穩定13例),差異有統計學意義(P＜0.05).1度皮疹和2～3度皮疹患者的中位疾病進展時間分彆為5.1和9.7箇月(P＜0.01).1度皮疹患者的中位生存期為10.0箇月,2～3度皮疹患者的中位生存期為14.6箇月(P＜0.01).有78.9%(60/76)的患者經治療後皮疹得到緩解.結論:阨囉替尼所緻皮疹是阨囉替尼臨床穫益的指標之一,且大多數患者可以耐受,給予恰噹的治療後可以穫得緩解.
목적:평개액라체니소치피진여림상료효지간적관계,병탐토피진치료적유효방법.방법:연구대상위2005년12월-2008년9월접수액라체니치료병발생피진적76례만기비소세포폐암(non-small cell lung cancer, NSCLC)환자,균경병리조직학혹세포학여이학진.액라체니치료방안위150 mg/d,매일련속복약직지질병진전혹출현불가내수적불량반응.기록피진엄중도,안조미국국립암증연구원통용독성표준(National Cancer Institute-Common Toxicity Criteria, NCI-CTC)대피진엄중도진행분급,병관찰기치료결국.결과: 76례환자발생피진적중위시간위8 d,기중1도피진27례(35.5%)、2도피진44례(57.9%)、3도피진5례(6.6%).1도화2～3도피진적질병공제솔분별위63.0%(부분완해5례、은정12례)화91.8%(부분완해32례、은정13례),차이유통계학의의(P＜0.05).1도피진화2～3도피진환자적중위질병진전시간분별위5.1화9.7개월(P＜0.01).1도피진환자적중위생존기위10.0개월,2～3도피진환자적중위생존기위14.6개월(P＜0.01).유78.9%(60/76)적환자경치료후피진득도완해.결론:액라체니소치피진시액라체니림상획익적지표지일,차대다수환자가이내수,급여흡당적치료후가이획득완해.
Objective:To evaluate the relationship between erlotinib-induced skin rash and clinical outcome and explore the effective way to prevent skin rash. Methods:The data from 76 non-small cell lung cancer(NSCLC) patients who experienced erlotinib-induced skin rash from Dec 2005 to Sep 2008 were collected. All the patients were confirmed with NSCLC by pathological and cytological examination and received erlotinib 150 mg/d till they had progressive disease or intolerable adverse reaction. The severity of skin rash was recorded and graded according to National Cancer Institute-Common Toxicity Criteria (NCI-CTC). The therapeutic outcome of skin rash was observed. Results:The skin rash develops as early as 3 days after commencement of erlotinib therapy, with median onset at 8 days. Twenty-seven (35.5%) patients experienced grade 1 skin rash, 44 patients (57.9%) had grade 2 and 5 cases (6.6%) had grade 3 skin rash. A statistically significant correlation was observed between skin rash and erlotinib therapy. The disease-controlling rate was 63.0% for grade 1 skin rash patients including 5 cases with partial remission and 12 cases with stable disease and 91.8% for grade 2/3 skin rash patients including 32 cases with partial remission and 13 cases with stable disease (P<0.05). The median time to progression(TTP) and median overall survival(OS) were prolonged in patients experienced grade 2/3 skin rash compared with those in patients with grade 1 skin rash (TTP: 5.1 months vs 9.7 months, P<0.01; OS: 10.0 months vs 14.6 months, P<0.01). The skin rash was alleviated in 60 out of 76 patients (78.9%). Conclusion:Skin rash is a potent surrogate marker of favorable outcome in patients who received erlotinib treatment. It was tolerable to most patients. Appropriate therapy may be useful in decreasing the severity of skin rash.
